Pharmacology, Toxicology and Pharmaceutical Science
Lomitapide
100%
Observational Study
100%
Familial Hypercholesterolemia
100%
Low Density Lipoprotein Cholesterol
51%
Monoclonal Antibody
50%
Kexin
42%
Serine Proteinase
42%
Subtilisin
42%
Adverse Event
27%
Ascorbic Acid
14%
Side Effect
14%
Coronary Artery Atherosclerosis
12%
Cardiovascular Disease
10%
Evolocumab
7%
Alirocumab
7%
Low Density Lipoprotein
7%
Microsomal Triglyceride Transfer Protein
6%
Disorders of Lipid and Lipoprotein Metabolism
6%
Event Free Survival
6%
Gastrointestinal Symptom
6%
Cardiovascular Risk
6%
Prematurity
6%
Combination Therapy
6%
Tolerability
6%
Antilipemic Agent
5%
Aminotransferase
5%
Fatty Liver
5%
Liver Fibrosis
5%
Medicine and Dentistry
Sex Difference
50%
Monoclonal Antibody
50%
Lomitapide
50%
Familial Hypercholesterolemia
50%
Observational Study
50%
Kexin
42%
Subtilisin
42%
Serine Proteinase
42%
Low Density Lipoprotein Cholesterol
31%
Ascorbic Acid
14%
Side Effect
14%
Adverse Event
12%
Arteriosclerotic Heart Disease
12%
Low-Density Lipoprotein
7%
Alirocumab
7%
Post-Hoc Analysis
6%
Gastrointestinal Distress
6%
Prematurity
6%
Combination Therapy
6%
Inborn Error of Lipid Metabolism
6%
Gender Difference
6%
Cardiovascular Risk
6%
Event Free Survival
6%
Immunology and Microbiology
Low-Density Lipoprotein
57%
Monoclonal Antibody
50%
Sex Difference
50%
Low Density Lipoprotein Cholesterol Level
33%
Lipid Metabolism
16%
Event Free Survival
16%
Vitamin C
14%
Evolocumab
7%
Alirocumab
7%
